1. Market Research
  2. > Pharmaceutical Market Trends
  3. > EyeGate Pharmaceuticals, Inc. - Product Pipeline Review - 2013

EyeGate Pharmaceuticals, Inc. - Product Pipeline Review - 2013

  • December 2013
  • -
  • Global Markets Direct
  • -
  • 31 pages

EyeGate Pharmaceuticals, Inc. - Product Pipeline Review - 2013

Summary

Global Market Direct’s pharmaceuticals report, “EyeGate Pharmaceuticals, Inc. - Product Pipeline Review - 2013” provides data on the EyeGate Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, EyeGate Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from EyeGate Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- EyeGate Pharmaceuticals, Inc. - Brief EyeGate Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of EyeGate Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of EyeGate Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the EyeGate Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate EyeGate Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of EyeGate Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the EyeGate Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with EyeGate Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of EyeGate Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Table Of Contents

EyeGate Pharmaceuticals, Inc. - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 4
EyeGate Pharmaceuticals, Inc. Snapshot 5
EyeGate Pharmaceuticals, Inc. Overview 5
Key Information 5
Key Facts 5
EyeGate Pharmaceuticals, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
EyeGate Pharmaceuticals, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Partnered Products 10
Partnered Products/Combination Treatment Modalities 11
EyeGate Pharmaceuticals, Inc. - Pipeline Products Glance 12
EyeGate Pharmaceuticals, Inc. - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
EyeGate Pharmaceuticals, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
EyeGate Pharmaceuticals, Inc. - Early Stage Pipeline Products 15
Discovery Products/Combination Treatment Modalities 15
EyeGate Pharmaceuticals, Inc. - Unknown Stage Pipeline Products 16
Unknown Products/Combination Treatment Modalities 16
EyeGate Pharmaceuticals, Inc. - Drug Profiles 17
dexamethasone acetate 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
EGP-Antibiotics 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
EGP-Wet Age Related Macular Degeneration 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
EyeGate Pharmaceuticals, Inc. - Pipeline Analysis 21
EyeGate Pharmaceuticals, Inc. - Pipeline Products by Therapeutic Class 21
EyeGate Pharmaceuticals, Inc. - Pipeline Products by Target 22
EyeGate Pharmaceuticals, Inc. - Pipeline Products by Route of Administration 23
EyeGate Pharmaceuticals, Inc. - Pipeline Products by Molecule Type 24
EyeGate Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action 25
EyeGate Pharmaceuticals, Inc. - Recent Pipeline Updates 26
EyeGate Pharmaceuticals, Inc. - Dormant Projects 28
EyeGate Pharmaceuticals, Inc. - Locations And Subsidiaries 29
Head Office 29
Appendix 30
Methodology 30
Coverage 30
Secondary Research 30
Primary Research 30
Expert Panel Validation 30
Contact Us 31
Disclaimer 31



List of Tables

EyeGate Pharmaceuticals, Inc., Key Information 5
EyeGate Pharmaceuticals, Inc., Key Facts 5
EyeGate Pharmaceuticals, Inc. - Pipeline by Indication, 2013 7
EyeGate Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 8
EyeGate Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 9
EyeGate Pharmaceuticals, Inc. - Partnered Products in Pipeline, 2013 10
EyeGate Pharmaceuticals, Inc. - Partnered Products/ Combination Treatment Modalities, 2013 11
EyeGate Pharmaceuticals, Inc. - Phase III, 2013 12
EyeGate Pharmaceuticals, Inc. - Phase II, 2013 13
EyeGate Pharmaceuticals, Inc. - Phase I, 2013 14
EyeGate Pharmaceuticals, Inc. - Discovery, 2013 15
EyeGate Pharmaceuticals, Inc. - Unknown, 2013 16
EyeGate Pharmaceuticals, Inc. - Pipeline by Therapeutic Class, 2013 21
EyeGate Pharmaceuticals, Inc. - Pipeline by Target, 2013 22
EyeGate Pharmaceuticals, Inc. - Pipeline by Route of Administration, 2013 23
EyeGate Pharmaceuticals, Inc. - Pipeline by Molecule Type, 2013 24
EyeGate Pharmaceuticals, Inc. - Pipeline Products by Mechanism of Action, 2013 25
EyeGate Pharmaceuticals, Inc. - Recent Pipeline Updates, 2013 26
EyeGate Pharmaceuticals, Inc. - Dormant Developmental Projects,2013 28



List of Figures

EyeGate Pharmaceuticals, Inc. - Pipeline by Top 10 Indication, 2013 6
EyeGate Pharmaceuticals, Inc. - Pipeline by Stage of Development, 2013 8
EyeGate Pharmaceuticals, Inc. - Monotherapy Products in Pipeline, 2013 9
EyeGate Pharmaceuticals, Inc. - Pipeline by Top 10 Therapeutic Class, 2013 21
EyeGate Pharmaceuticals, Inc. - Pipeline by Top 10 Target, 2013 22
EyeGate Pharmaceuticals, Inc. - Pipeline by Top 10 Route of Administration, 2013 23
EyeGate Pharmaceuticals, Inc. - Pipeline by Top 10 Molecule Type, 2013 24
EyeGate Pharmaceuticals, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2013 25



Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

cAMP and cAMP Inhibited cGMP 3%,5% Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

cAMP and cAMP Inhibited cGMP 3',5' Cyclic Phosphodiesterase 10A (Phosphodiesterase 10A1 or Phosphodiesterase 10A7 or PDE10A or EC 3.1.4.17 or EC 3.1.4.35) - Pipeline Review, H2 2016 Summary Global Markets ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Potassium Voltage Gated Channel Subfamily KQT Member 3 (Potassium Channel Subunit Alpha KvLQT3 or Voltage Gated Potassium Channel Subunit Kv7.3 or KCNQ3) - Pipeline Review, H2 2016 Summary Global Markets ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.